Neurology Central

Neuro Central on Instagram

0
Click the links below to discover the full articles.
Haven’t followed us yet? Navigate here to keep up-to-date with our Instagram journey.

Techniques and emerging approaches – cerebral organoids
This month we’re focusing on techniques and emerging approaches – take a look at our infographic to learn more about the use of cerebral organoids as an emerging therapy; including key research, ethical questions and future applications.

A peek into the office: World Cup sweepstake
Things are getting exciting here at Neuro Central HQ for the Fifa 2018 World Cup! Our team have picked out Denmark, Iceland, Russia, Colombia and France for the office sweepstake – will we stand a chance at winning? Keep up-to-date with our office sweepstakes by following us on Instagram here.

Alzheimer’s disease: Phase III clinical trials of lanabecestat to discontinue
Eli Lilly (IN, USA) and AstraZeneca (Cambridge, UK) have announced that they are discontinuing the global Phase III clinical trials of lanabecestat for the treatment of Alzheimer’s disease. The decision has been based on recommendations by an independent data monitoring committee.

Investigational gene therapy licensed for Parkinson’s disease: industry news round-up
This week’s industry news round-up reveals the latest updates around spinal muscular atrophy and the discontinuation of olesoxime by Roche, an investigational gene therapy licensed for Parkinson’s disease and Biogen entering an agreement to acquire TMS-007 for acute stroke.

Share:

Leave A Comment